PDE5 inhibition and Alzheimer’s disease risk: a mendelian randomisation study
Alcalde-Herraiz M. et al, (2024)
Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes.
Alcalde-Herraiz M. et al, (2024), Nat commun, 15
Genome-wide association studies of COVID-19 vaccine seroconversion and breakthrough outcomes in UK Biobank.
Alcalde-Herraiz M. et al, (2024), Nat commun, 15
Modifiable lifestyle factors and the risk of post-COVID-19 multisystem sequelae, hospitalization, and death.
Wang Y. et al, (2024), Nat commun, 15
Relationship between HLA genetic variations, COVID-19 vaccine antibody response, and risk of breakthrough outcomes.
Xie J. et al, (2024), Nat commun, 15
The cause-effect relationship between sclerostin levels, cardiovascular biomarkers, risk factors, and cardiovascular disease
Prieto-Alhambra D. et al, (2023)
Sclerostin inhibition and cardiovascular risk: Triangulating the evidence using Mendelian randomization methods
Alcalde-Herraiz M. et al, (2023), Pharmacoepidemiology and drug safety, 32, 462 - 463
Sclerostin inhibition, cardiovascular biomarkers, risk factors, and clinical outcomes: A Mendelian randomization analysis using UK Biobank data
Alcalde-Herraiz M. et al, (2023), Pharmacoepidemiology and drug safety, 32, 52 - 53